Novartis confirms unconstrained PLUVICTO® supply and significantly expands treatment centers
US drug shortage status resolved, as Novartis significantly scales up production of PLUVICTO®.
Novartis Financial Results - Q3 2023
Our treatment centre locator will help you find a facility local to your patient, discover what RLI/RLT they offer, and make a referral so they can be treated closer to home.
Novartis PLUVICTO® shows clinically meaningful and highly statistically significant rPFS benefit in patients
Impressive data and promising Pluvicto results at the 2023 European Society for Medical Oncology (ESMO) Congress.
Novartis LUTATHERA® demonstrates clinically meaningful progression-free survival in first line advanced (GEP-NETs)
LUTATHERA® results represent a significant development in advanced cancer care.
- Press ReleasesNovartis Financial Results - Q3 2023
Novartis Financial Results - Q3 2023
- Press ReleasesNovartis confirms unconstrained PLUVICTO® supply and significantly expands treatment centers
US drug shortage status resolved, as Novartis significantly scales up production of PLUVICTO®.
- Press ReleasesNovartis PLUVICTO® shows clinically meaningful and highly statistically significant rPFS benefit in patients
Impressive data and promising PLUVICTO® results at the 2023 European Society for Medical Oncology (ESMO) Congress.
- Press ReleasesNovartis LUTATHERA® demonstrates clinically meaningful progression-free survival in first line advanced (GEP-NETs)
LUTATHERA® results represent a significant development in advanced cancer care.